1University Of Health Sciences Erzurum Education And Research Hospital, Department of Urology, Erzurum, Turkey
2Bilecik State Hospital, Clinic of Urology, Bilecik, Turkey
3Binali Yildirim University, Faculty of Medicine, Department of Urology, Erzincan, Turkey
Aim: The aim of this study is to present the surgical, oncologic and functional results of the first 34 robotic radical prostatectomy (RARP) procedures performed in our clinic.
Material and Methods: Data of 34 patients who underwent RARP between July 2017 and October 2019 were evaluated.
Results: The mean patient age was 58.73±4.94 years, and the mean preoperative serum prostate-specific antigen level was 8.9±2.07 ng/mL. Bilateral neurovascular bundle (NVB) sparing, unilateral NVB-sparing, and non-NVB-sparing surgery were performed in 7.5, and 22 cases, respectively. The mean prostate weight was 58.73±26.03g. Anterior reconstruction suture was performed in 22 (64.7%) cases. Mean console time, intraoperative blood loss, duration of hospital stay, and urethral catheter removal time were 195.2±14.03min, 120.3±21.2cc, 7.34±1.62 days, and 7.26±1.26 days, respectively. Biochemi¬cal recurrence was observed in two patients, one of whom received maximal androgen blockage (MAB), and the other one received pelvic radiotherapy+MAB. All the patients with at least one-year follow-up were fully continent (0 pads/day). Of the 16 (47%) patients with no preoperative erectile dysfunction (ED) and with at least three-month follow-up, 9 (62.5%) had no ED, with or without any additional medica¬tion including phosphodiesterase-5 (PDE5) inhibitors.
Conclusion: RARP is a safe minimally invasive procedure with acceptable morbidity, excellent operative, pathological and oncological outcomes, and satisfactory functional results.
Keywords: Robot asisted radical prostatectomy; prostat ca; D’amico